RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold
A day after Biogen rattled the biopharma world with the news that its lead late-stage therapy aducanumab proved worthless in treating Alzheimer’s — a disaster that may drive a stake through the heart of the amyloid beta theory once and for all — the big biotech’s partners at Eisai have come up with their next big move.
Right in the wake of a 35% plunge in their stock value, Eisai $ESALY is starting a Phase III study involving 1,566 Alzheimer’s patients with mild cognitive impairment for the controversial Alzheimer’s drug BAN2401. The anti-amyloid antibody was the center of a firestorm of criticism over a tardy reveal that researchers had pulled high-risk patients out of their last study, potentially warping the positive results that were claimed, leaving that drug under a dark cloud.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.